Longer-Term Follow-Up of A Phase 2 Study (checkmate 063) of Nivolumab in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
Leora Horn,Naiyer A. Rizvi,Julien Mazieres,David Planchard,Thomas E. Stinchcombe,Grace K. Dy,Scott J. Antonia,Herve Lena,Elisa Minenza,Bertrand Mennecier,Gregory A. Otterson,Luis T. Campos,David R. Gandara,Benjamin P. Levy,Suresh G. Nair,Gerard Zalcman,Juergen Wolf,Paul Paik,Ang Li,Dong Xu,Jaclyn Neely,Zhenhao Qi,Christopher Harbison,Mark Lynch,Suresh S. Ramalingam JOURNAL OF THORACIC ONCOLOGY（2015）
关键词
Nivolumab,PD-L1,Squamous cell NSCLC,Immunotherapy
AI 理解论文
溯源树
样例
